GO 203 2c

Drug Profile

GO 203 2c

Alternative Names: GO2032c

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genus Oncology
  • Developer Dana-Farber Cancer Institute; Genus Oncology
  • Class Antineoplastics; Peptides
  • Mechanism of Action Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Discontinued Solid tumours

Most Recent Events

  • 06 Mar 2018 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) (Genus Oncology website, March 2018)
  • 06 Mar 2018 Phase-II clinical trials in Acute myeloid leukaemia (Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in USA (IV) (Genus Oncology website, March 2018)
  • 06 Mar 2018 Dana-Farber Cancer Institute and The Leukemia and Lymphoma Society completes phase I of a phase I/II trial in Acute myeloid leukaemia (Monotherapy, Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in USA (Genus Oncology website, March 2018) (NCT02204085)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top